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Osteoporosis medicines reduce osteoporotic fractures. There is a very strong negative 31 
correlation between the consumption of medicines and the price of an average daily dose 32 
indicating that affordability is a key factor that could increase consumption of 33 
antiosteoporotic medicines and through that reduce fractures. 34 
ABSTRACT 35 
Purpose Osteoporosis is a major cause of morbidity and mortality in the modern world. Our 36 
study aims to describe the trends in incidence of hip fractures in relation to drug utilization 37 
patterns and the average price of antiosteoporotic medicines in Estonia. 38 
Methods Data on hip fractures was obtained from the medical claims database of Estonian 39 
Health Insurance Fund (EHIF). Consumption and price data was obtained from the Estonian 40 
State Agency of Medicines (SAM). Consumption is presented using WHO defined daily 41 
doses methodology and the prices reflect the average wholesale price of medicines. 42 
Results From 2004 to 2010 there was a non-significant increasing trend in standardized hip 43 
fracture incidence in Estonia, but from 2010 to 2015 the trend turned to a significant decrease 44 
of 4.5% per year. The consumption of osteoporosis medication increased significantly from 45 
2004 to 2009 by yearly average of 41.2%. After 2009 the consumption levelled. On contrast 46 
the average price of one daily dose of osteoporosis medication decreased significantly from 47 
2004 to 2009 by 16.9% per year and the decrease also levelled after 2009. This gives a very 48 
strong negative correlation of -0,93 (p<0,001) between the consumption of antiosteoporotic 49 
medication and the average price of a daily dose of medication during the study period.  50 
Conclusions The statistically significant decline of standardized incidence of hip fractures 51 
from 2010 onward could at least in part be the result of the high increase in consumption of 52 
antiosteoporotic medicines which in turn is strongly negatively correlated with the average 53 
price of osteoporosis medicines. 54 
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1. INTRODUCTION 57 
Osteoporosis is a major cause of morbidity and mortality in the modern world [1]. It is 58 
characterized by reduced bone mass and disruption of bone architecture, resulting in increased 59 
bone fragility and increased fracture risk [2]. Fractures cause pain, degrade quality of life and 60 
are often disabling [3]. Osteoporosis itself is usually asymptomatic until a fracture occurs [4] 61 
and osteoporosis has clinical and public health importance only because of these fractures [5].  62 
The efficacy of drug treatment in osteoporosis ultimately depends on the demonstration of a 63 
reduction in the risk of fracture [6]. Today there is a wide selection of effective 64 
pharmacological treatment options available (bisphosphonates, the parathyroid hormone 65 
teriparatide, the selective estrogen receptor modulator raloxifene, denosumab and strontium 66 
ranelate) [7]. 67 
The secular trends of fractures have been shown to follow different patterns in different parts 68 
of the world [8] indicating the need for local research on the subject. Understanding the 69 
reasons for the changes in rates of hip fractures may help understand ways to reduce rates of 70 
hip fractures worldwide [8]. The possible drivers for changes in fracture rates are osteoporosis 71 
medication use,  urbanization, birth cohort effects, changes in bone mineral density and BMI 72 
and/or lifestyle interventions such as smoking cessation, improvement in nutritional status and 73 
fall prevention [9]. 74 
The influence of osteoporosis medication use on the trend of fractures has been pointed out as 75 
one of the main reasons for the decrease in fracture incidence [10, 11]. But it has been 76 
acknowledged that the results need to be also verified in local populations and countries [12]. 77 
Although the connection between the increasing utilization of medication and the price of 78 
drugs has been suggested for other drug classes [13] specific data concerning the changes in 79 
utilization of osteoporosis drugs depending on their price is scarce. 80 
The trends in incidence of hip fractures has been studied before in Estonia [14]. Our study 81 
aimed to prolong the time period of the analysis and describe the trends in relation to drug 82 
utilization pattern. In addition we studied the changes in average price of daily dose of 83 
antiosteoporotic medicines in Estonia. The correlation between osteoporosis medicines 84 
consumption and the price of medicines has not been very well established yet and could 85 





2. METHODS 89 
2.1. Hip fractures 90 
We used hip fractures as a proxy for osteoporotic fractures as they are considered the most 91 
serious consequences of osteoporosis [15] with 1-year mortality around 20-25% around the 92 
globe [16]. Data on incidence of hip fractures was obtained from the medical claims database 93 
of the Estonian Health Insurance Fund (EHIF). Health care providers submit treatment bills to 94 
EHIF and we used those bills to identify the number of hip fracture diagnosis according to 95 
ICD-10 (S72.0-S72.2). Only the initial bill with the diagnosis was taken into account for each 96 
patient in any given year. The EHIF database covers the insured population of Estonia, which 97 
is around 95% of total population and 100% of pensioners [17]. We included both men and 98 
women and all age-groups in our study as the consumption data also included total 99 
consumption of osteoporosis medicines. Data on population in a given year was obtained 100 
from Statics Estonia [18] that publishes the official population of Estonia. As the study period 101 
is 11 years long and Estonian population is ageing, incidence of hip fractures is presented as 102 
standardized incidence rates using the age distribution of the Estonian population of the year 103 
2009 in 5-year age groups as the base of standardization. 104 
2.2 ATC/DDD methodology 105 
Drug utilization was analyzed using the anatomical therapeutic chemical (ATC) classification 106 
and defined daily dose (DDD) methodology that is developed and maintained by the World 107 
Health Organization Collaborating Centre for Drug Statistics Methodology. The methodology 108 
is used in most of the European countries to serve as the tool for drug utilization research. The 109 
national statistics of the medicines' consumption gathered by governmental bodies is usually 110 
based on this methodology to keep track of changes in drug utilization [17]. 111 
All the active substances used in Estonia that affect bone structure and mineralization are 112 
included in the ATC group M05B, which is further divided into groups of plain 113 
bisphosphonates, bisphosphonate combinations and other drugs affecting bone structure and 114 
mineralization (e.g. strontium ranelate and denosumab). In terms of efficacy against hip 115 
fractures these substances are rather similar [19]. 116 
The defined daily dose is the assumed average maintenance dose per day for a drug used for 117 
its main indication in adults. It is described as a unit of measurement and is not always 118 
reflecting the recommended dose or the actual prescribed daily dose. For drugs against 119 
osteoporosis this is not the case as the doses used do not differ and the defined daily doses 120 
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applied by the WHO depict very well the actual doses used. This allows to evaluate the 121 
number of patients receiving the treatment in a period of time rather accurately. 122 
The number of DDDs is reported as per 1000 inhabitants per day (DDD/1000 inhabitants/day 123 
or DID). We used the 2016 version of the ATC/DDD classification in the study. 124 
Consumption data included in the study is available on the internet published by the Estonian 125 
State Agency of Medicines (SAM) [20] and represent wholesale sales data to general or 126 
hospital pharmacies. The data covers 100% of sales of antiosteoporotic medicines in Estonia. 127 
The average prices of medicines daily doses were also obtained from SAM and were 128 
calculated using wholesale prices with value added tax (VAT) excluded. The currency in 129 
Estonia was changed from kroon to euro in the beginning of 2011, but as the exchange rate 130 
was always the same (1 euro=15.647 kroons) the prices in kroons were just calculated to 131 
euros. 132 
2.3 Data analysis 133 
Statistical analysis were done using MS Excel and Joinpoint Regression Program, Version 134 
4.3.1.0. Joinpoint is statistical software for the analysis of trends using joinpoint models 135 
enabling to test if an apparent change in trend is statistically significant. Results are presented 136 
as average annual percent change (APC) over time period.  The tests of significance use a 137 
Monte Carlo Permutation method [21]. We consider statistically significant p-values less than 138 
0.05. 139 
Relation between the consumption of antiosteoporotic medication and the average price of a 140 
daily dose of medication is presented by Spearman correlation coefficient as both indicators 141 
are non-normally distributed. 142 
3. RESULTS 143 
On average there were around 1500 hip fractures per year in Estonia during the study period. 144 
The standardized rate of hip fractures in 5-year age groups in Estonia and the Estonian 145 
population in the years 2004-2015 is presented in table 1. 146 
As shown on figure 1 the trend of standardized hip fractures incidence rate in Estonia from 147 
2004 to 2015 can be divided into two different periods. In the first period from 2004 until 148 
2010 there was an increasing trend of hip fractures on average 1.19% per year with the 149 
highest fracture rate in 2009 but the trend was not statistically significant. Then the trend 150 
changed direction and from 2010 to 2015 there was an average annual decrease in 151 
standardized incidence rates of hip fractures of 4.46% (p<0.05).  152 
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The consumption of medication against osteoporosis during our study may also be divided 153 
into two different periods (figure 2). Initially the increase in consumption was very steep with 154 
an average of 41.21% (p<0.05) per year. This period raised the consumption from 0.8 155 
DDD/1000 inhabitants/day in 2004 to 3.9 DDD/1000 inhabitants/day in 2009, which is almost 156 
a 5-fold increase. Since 2009 the consumption levelled with a statistically non-significant 157 
trend for increase until the end of the study period. 158 
The change in preferred active substances in Estonia is shown on figure 3. The choice of 159 
drugs increased over the years and the preferences of active substances changed during the 160 
study period. In 2004 and 2005 only plain bisphosphonates were used. In 2006 the first 161 
combined preparation appeared on the Estonian market - the combination of alendronic acid 162 
and colecalciferol. From 2006 the only addition to the selection of active substances has been 163 
denosumab in 2010. In 2015 the medicine with the highest share of consumption was 164 
alendronic acid and colecalciferol combination with 59% out of the total of antiosteoporotic 165 
drugs. 166 
The average price of a daily dose of antiosteoporotic medication moved in opposite direction 167 
to the consumption (figure 2). From the year 2004 to 2009 the average price decreased on 168 
average 16.85% (p<0.05) every year. From 2009 to 2015 the decrease in the average price of 169 
a daily dose was less expressed with an average annual decrease of 4.74% which was not 170 
statistically significant. 171 
There is a very strong negative correlation of -0.94 (p<0.001) between the consumption of 172 
antiosteoporotic medication and the average price of a daily dose of medication during the 173 
study period. 174 
4. DISCUSSION 175 
Due to aging of population and changes in people’s lifestyle the overall number of fractures 176 
would be expected to increase as a result [22]. This is what we saw for Estonia for the years 177 
2004 to 2009 as our study found a similar trend in the standardized incidence rate of hip 178 
fractures as reported before [14] with the rate increasing initially but then starting to decrease. 179 
The trend is similar to what has been observed in most of the developed countries with initial 180 
increase in trend and a following decrease [8]. The turning point was a bit earlier in the 181 
western countries though with the trend turning to decline for instance in Scandinavia in the 182 
1990s [9] while in Estonia the turning point was in the late 2000s. The main reason for the 183 
increase in hip fractures has been speculated to be urbanization [9]. The decline on the other 184 
hand might be the result of several factors. Increase of osteoporosis medicines use for one but 185 
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also the increase of average BMI, improved general health, decline in the number of smokers 186 
[23] and falls prevention campaigns [24]. The number of women over 55 with BMI over 25 187 
did not change drastically in Estonia in the 1990s and the 2000s with the average percent 188 
being 70.0 in the 1990s and 71.5 in the 2000s [25]. The percent of non-smokers amongst 189 
women aged over 55 has decreased in Estonia as in the 1990s on average 81% stated 190 
themselves to be non-smokers but 66% stated this in the 2000s [25]. So in the Estonian 191 
context the decrease in hip fracture incidence seems to be more related to general health 192 
improvement and medicines consumption as we have had no falls prevention campaigns. 193 
Jürisson, et al. [14] also discuss that the reduction in fracture rate can be explained in addition 194 
to the increase in bisphosphonate use by reductions in falls-related comorbidity because of 195 
improved general health and prevention and treatment of chronic diseases. The life 196 
expectancy at 65 in Estonian women increased from 17.9 to 20.3 years (2.4 years) during our 197 
study period [25].  198 
There was virtually no effective osteoporosis treatment in Estonia in the 1990s and the use of 199 
bisphosphonates started in the early 2000s [20]. Initially the consumption was still extremely 200 
low, because the medications were very expensive and there was no reimbursement by EHIF. 201 
There are several factors that influence drug use but the most important of those are the 202 
availability and affordability of medication [26]. What helped to increase the number of 203 
patients getting antiosteoporotic medicines in the 2000s was the number of clinical trials 204 
carried out in Estonia at that time. Approximately 20 trials were conducted and in addition to 205 
the patients who got the intervention also the patients who were in the control group got 206 
vitamin D and calcium supplements and information about their condition, which in turn 207 
could help decrease the number of fractures. 208 
Reimbursement of 75% (or 90% if the patient was older than 63) of the cost of the drug by 209 
EHIF for patients with a fragility fracture and DXA T-score ≤ -2.5SD was introduced in 2007. 210 
Before the reimbursement was 50% but no more than 12.8€ per prescription. The 75% 211 
reimbursement group did not have such an upper limit which made the drugs considerably 212 
cheaper for patients. Also the introduction of generics was during the same period with the 213 
first alendronic acid generics introduced in 2007 after which the total consumption more than 214 
doubled within just two years. With medications being more affordable to patients the 215 
adherence to treatment is also expected to improve [27] and patients are able to take the drugs 216 
for longer periods, which is vital with quality of treatment kept in mind. This could also work 217 
the other way around of course as doctors and patients become more aware of the importance 218 
of medication adherence and implement treatment better than before the consumption of 219 
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medicines increases. It has been shown that in addition to medicines’ cost also interpretation 220 
of one’s disease and perception of possible benefits and risks of treatment improves adherence 221 
[28]. 222 
The consumption of antiosteoporotic drugs has not increased much since 2010. It can be 223 
related to the fact that reimbursement system for the drugs against osteoporosis is not changed 224 
and there is still only a limited group of patients (fragility fracture + DXA T-score ≤ -2.5SD) 225 
who get medications reimbursed at 75% or 90% (patients over 63) rate and others have a 50% 226 
co-payment, which makes the drugs still rather expensive for older people who need them the 227 
most. Fisher, et al. [12] saw an increase of hip fracture incidence very quickly after drop in 228 
the number of bisphosphonate prescriptions. We saw a continuing decline but the Estonian 229 
consumption steadied not decreased. It has been argued that the consumption of osteoporosis 230 
medication is responsible for only a part of the change in incidence of hip fractures [23] but 231 
the turning points in trends of consumption and fractures have been shown to be compatible 232 
also in other studies [10, 15] as we see in Estonia - four years after the introduction of higher 233 
reimbursement rate for antiosteoporotic medicines the standardized incidence rate of hip 234 
fractures started to decrease. 235 
As we see a very strong negative correlation between the average price of a daily dose and the 236 
overall consumption one could expect even higher consumption if patients in risk of fracture 237 
in addition to patients with an actual fracture would be offered higher reimbursement rate. 238 
Price of medication is still rather substantial for this group of patients as for most patients who 239 
get higher reimbursement the medicines should be affordable. The consumption of 240 
antiosteoporotic drugs is not to be regarded as sufficient in Estonia as the population at risk of 241 
osteoporosis is assessed to be around 80 000 people [29] and according to our study, 242 
treatment was received daily by approximately 6300 patients in 2015. This is < 10% of 243 
patients with osteoporosis risk. The defined daily dose methodology allows assessing the 244 
average number of patients taking osteoporosis medication each day though. The number of 245 
patients who have had medication is bound to be higher as medicines are not taken 246 
continuously throughout a year and some patients stop taking the medicine after a while and 247 
others start treatment at some point. The same conclusions are stated also in EU osteoporosis 248 
report that use of pharmacological prevention of osteoporosis is significantly less than 249 
optimal, suggesting that a change in healthcare policy concerning the disease is warranted 250 
[29].  251 
Current data suggest that consumption of drugs against osteoporosis might have an effect on 252 
fracture rate and price of medication has an effect on consumption. What will happen with hip 253 
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fracture rates in a few years as the increase in consumption has stopped and levelled remains 254 
to be seen. The use of antiosteoporotic drugs is one of the factors that have an effect on hip 255 
fracture rate and more detailed analysis about gender and fracture type may give us additional 256 
information. As the drug sales data are not patient gender or age specific we were not able to 257 
follow importance of these factors during this study. Also treatment duration, adherence and 258 
other factors showing patient behaviour are not reflected in sales data and an additional study 259 
is needed to investigate this in depth using actual prescriptions data. 260 
The main limitations of the study lie with the methods of data collection. As EHIF data 261 
captures initial bills for any given year if a patient had several fractures within a year it would 262 
not be registered in the data. The number of multiple fractures in a year is supposedly not big 263 
though. The drug consumption data is based on sales data from drug wholesalers and depicts 264 
sales to pharmacies, so it does not directly show the amount of medicines received by patients 265 
and furthermore even if a patient purchased the medicines from a pharmacy it is unknown 266 
whether one actually administered them.  267 
5. CONCLUSIONS 268 
The age standardized incidence of hip fractures turned to a statistically significant decline 269 
after a trend for increase in the beginning of the study. Though improved general health and 270 
prevention and treatment of chronic diseases contribute to this it could be at least in part the 271 
result of the high increase in the consumption of antiosteoporotic medications during the first 272 
decade of the century. 273 
The increase in consumption of medicines correlates in turn strongly with the decline in the 274 
average daily dose price of oral antiosteoporotic medicines. The price cannot drop indefinitely 275 
of course which means that further reduction in expenses to patients in Estonia can come from 276 
broadening the reimbursement to patients in risk of osteoporotic fractures rather than offering 277 
reimbursement only for patients who have had a fracture. 278 
Our study describes the trends in hip fracture incidence, consumption of antiosteoporotic 279 
medicines and the price of these medicines. Whether there is a causal relationship between 280 
these factors is hard to establish but it is certain that further action to prevent osteoporosis and 281 
the resulting fractures is needed and the measures taken should be many fold ranging from 282 









  290 
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7. TABLES 375 
Table 1. Population in Estonia by age groups and Estonian 2009-standardized incidence rates 376 
per 100,000 persons in Estonia in the years 2004–2015 377 
  Population 
Age 
group 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
0-1 13,560 14,155 14,590 15,275 15,825 15,870 15,855 15,329 14,374 13,801 13,603 
1-4 51,340 52,125 53,305 54,990 57,260 59,635 61,395 62,683 62,673 61,100 59,090 
5-9 62,845 61,935 61,495 61,515 62,335 63,615 64,955 66,631 69,019 71,692 74,007 
10-14 84,970 77,795 72,070 67,355 63,630 61,535 60,655 60,208 60,144 60,830 62,111 
15-19 102,700 102,170 100,040 96,200 90,580 83,465 76,465 70,908 66,327 62,666 60,576 
20-24 98,810 98,920 98,640 99,035 99,860 100,435 100,355 98,334 94,437 88,927 82,072 
25-29 95,935 95,205 94,545 94,045 94,310 95,195 95,605 95,596 96,172 97,120 97,848 
30-34 97,320 96,425 95,070 93,965 93,280 92,625 91,955 91,331 90,864 91,187 92,268 
35-39 90,545 90,795 91,935 93,430 94,330 94,250 93,540 92,438 91,390 90,607 90,087 
40-44 98,630 95,950 92,590 89,450 87,725 87,375 87,945 89,376 90,951 91,763 91,760 
45-49 98,090 97,800 97,545 97,195 96,090 94,505 92,225 89,282 86,559 85,011 84,741 
50-54 92,485 92,605 92,895 92,670 92,915 93,260 93,245 93,372 93,351 92,546 91,181 
55-59 78,625 83,300 86,165 87,290 87,450 87,135 87,515 88,135 88,256 88,652 89,107 
60-64 73,495 69,090 65,935 65,380 68,265 72,985 77,530 80,492 81,843 82,177 82,027 
65-69 73,495 74,760 75,415 74,540 70,790 66,345 62,595 59,957 59,659 62,500 67,048 
70-74 60,825 59,630 59,295 59,960 61,620 63,835 65,220 66,141 65,774 62,703 58,874 
75-79 47,290 48,655 49,715 50,300 49,960 48,920 48,305 48,410 49,473 51,284 53,415 
80-84 25,725 27,745 29,475 30,970 32,430 33,745 34,950 36,047 36,852 36,955 36,468 
85+ 15,865 15,715 16,090 17,115 18,435 19,785 21,165 22,769 24,578 26,476 28,262 
Total 1,362,550 1,354,775 1,346,810 1,340,680 1,337,090 1,334,515 1,331,475 1,327,439 1,322,696 1,317,997 1,314,545 
  
 
Standardized hip-fracture incidence per 100,000 
Age 
group 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
0-1 7.4 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 
1-4 3.9 1.9 0.0 1.8 5.2 3.4 3.3 0.0 3.2 1.6 3.4 
5-9 1.6 3.2 3.3 4.9 0.0 0.0 0.0 3.0 0.0 0.0 0.0 
10-14 3.5 7.7 2.8 4.5 3.1 11.4 4.9 5.0 1.7 4.9 0.0 
15-19 5.8 2.9 7.0 5.2 4.4 6.0 3.9 0.0 1.5 4.8 5.0 
20-24 2.0 2.0 3.0 3.0 2.0 1.0 1.0 9.2 3.2 2.2 1.2 
25-29 3.1 1.1 0.0 3.2 3.2 5.3 4.2 5.2 2.1 12.4 2.0 
30-34 9.2 4.1 4.2 6.4 6.4 5.4 7.6 4.4 6.6 2.2 2.2 
35-39 9.9 18.7 12.0 6.4 10.6 10.6 13.9 15.1 0.0 6.6 3.3 
40-44 9.1 20.8 16.2 8.9 25.1 10.3 6.8 19.0 9.9 10.9 9.8 
45-49 23.4 33.7 39.0 17.5 31.2 32.8 26.0 32.5 24.3 25.9 8.3 
50-54 45.4 43.2 42.0 48.6 44.1 42.9 47.2 38.6 52.5 33.5 36.2 
55-59 61.0 73.2 68.5 64.2 54.9 72.3 65.1 68.1 75.9 58.7 61.7 
60-64 102.0 141.8 98.6 123.9 106.9 112.4 126.4 119.3 84.3 101.0 106.1 
65-69 178.2 173.9 184.3 154.3 132.8 180.9 190.1 178.5 140.8 129.6 122.3 
70-74 256.5 318.6 278.3 250.2 284.0 278.8 297.5 287.3 231.1 256.8 237.8 
75-79 507.5 452.2 500.9 453.3 530.4 570.3 490.6 518.5 430.5 454.3 378.2 
15 
 
80-84 929.1 947.9 939.8 881.5 1103.9 1066.8 1021.5 951.5 827.6 871.3 836.3 
85+ 1960.3 2055.4 1939.1 1986.6 2017.9 2259.3 2116.7 2130.1 2123.9 1926.3 1836.4 
Total 109.9 116.8 112.0 106.4 116.1 123.2 118.1 117.4 103.0 102.5 94.4 
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8. FIGURES 381 
 382 
Fig. 1 The standardized incidence rate and the modelled trend of hip fractures (ICD-10 codes 383 
S72.0-S72.2) per 100,000 persons in Estonia in 2004-2015. 384 
 385 
 386 
Fig. 2 The actual and modelled trends of consumption of osteoporosis medication represented 387 
as the number of defined daily doses per 1000 inhabitants per day (DDD/1000/day) and the 388 





Fig. 3 The consumption of drugs against osteoporosis (ATC group code M05B) in Estonia in 392 
2004 to 2015 expressed as the proportion of different active substances used out of the total. 393 
 394 
